细胞周期蛋白依赖性激酶抑制物p27kip1在喉癌中的表达及意义

目的研究p27kip1在喉癌组织中的表达水平,探讨对喉癌患者的预后判断价值.方法采用免疫组化法检测44例喉癌组织p27kip1蛋白表达水平.结果本组44例中,p27kip1蛋白表达阳性31例,占70.5%,低表达者27例,占61.4%.喉癌组织p27kip1蛋白低表达;T1～2级(27.3%),明显少于T3～4级(72.7%)(P＜0.05);淋巴结转移组(80.8%),明显高于无淋巴结转移组(33.3%)(P＜0.05).结论细胞周期蛋白依赖性激酶抑制p27kip1表达与喉癌T分期及淋巴结转移密切相关,在喉癌中具有一定预后价值.     

p27与Ki-67联合检测对乳腺癌的预后意义

 目的　探讨联合检测细胞周期抑制剂p27和核蛋白Ki-67对乳腺癌的预后意义。方法　应用免疫组织化学方法检测手术切除并经术后病理证实的86例乳腺癌患者组织中p27和Ki-67的表达,利用Log-Rank检验行生存分析;COX比例风险模型行单因素及多因素分析。结果　Log-Rank检验显示p27低表达且Ki-67高表达者无瘤生存期明显缩短（χ2＝7.56;P＝0.003）;COX单因素分析提示淋巴结转移（P＝0.008）、肿瘤大小（P＝0.002）、p27低表达（P＝0.001）、Ki-67高表达（P＝0.015）均是影响乳腺癌患者无瘤生存率的因素,多因素分析提示p27低表达与Ki-67高表达同时存在是影响乳腺癌患者无瘤生存率的最显著的预后因子（P＝0.008）。结论　对乳腺癌组织中p27和Ki-67的检测有利于评估乳腺癌患者的预后,p27低表达及Ki-67高表达预示乳癌患者预后差,两者同时检测有助于提高对乳腺癌预后判断的准确性。     

p27kipl和Ki-67蛋白在非霍奇金淋巴瘤中的表达及临床意义

目的 探讨p27^kipl和Ki-67蛋白在非霍奇金淋巴瘤(non-Hodgkin’s lymphoma，NHL)中的表达及临床意义。方法 采用免疫组化方法检测100例NHL及20例反应性增生淋巴结中p27^kipl和Ki-67蛋白的表达情况，结合临床及病理资料进行统计分析。结果 p27^kipl蛋白在反应性增生淋巴结(不包括生发中心)中的阳性率明显高于NHL，随着肿瘤侵袭性的增加，p27^kipl表达水平下降。Ki-67蛋白在反应性增生的淋巴结(不包括生发中心)中的阳性率明显低于NHL，其表达水平随着肿瘤的侵袭性增加而上升。NHL中p27^kipl蛋白的阳性率与Ki-67表达水平呈负相关。结论 p27^kipl与NHL的发生发展有关，联合检测p27^kipl及Ki-67蛋白水平可为NHL的临床诊断和治疗提供参考。     

非小细胞肺癌组织中Skp2的表达及其与p27kip1和Ki-67蛋白表达的关系

目的:探讨Skp2的表达在非小细胞肺癌(nonsmallcelllungcancer,NSCLC)发生发展中的作用,及其与p27kip1和Ki67蛋白表达的关系。方法:应用免疫组化SP法检测Skp2、p27kip1和Ki67三种蛋白在60例NSCLC和20例正常支气管黏膜上皮组织中的表达。结果:NSCLC组织中Skp2蛋白表达的阳性率为48.33%(29/60),显著高于正常支气管黏膜上皮组织中的表达,P=0.000。Skp2的表达与肿瘤的组织学类型、肿瘤细胞的分化程度、TNM分期、淋巴结转移和患者吸烟与否显著相关,P值分别为0.038、0.005、0.019、0.010和0.002,但与患者的年龄及性别无关,P值分别为0.833和0.281。NSCLC组织中Skp2表达与p27kip1表达呈显著负相关,P=0.001;而与Ki67表达呈显著正相关,P=0.027。结论:Skp2在NSCLC组织中表达是上调的,可能是通过作用于细胞周期调控蛋白p27kip1,加速了对p27kip1泛素化依赖的蛋白降解,使其表达及代谢发生异常,导致细胞周期失控并促进细胞异常增殖,从而参与了NSCLC的发生和发展。     

视网膜母细胞瘤组织中 Ki-67、PTEN 表达的变化

目的：探讨视网膜母细胞瘤组织中 Ki-67、PTEN 表达的变化及其临床意义。方法采用免疫组化S-P 法检测97例视网膜母细胞瘤和28例正常视网膜组织中 Ki-67、PTEN 的表达水平,并分析两者与视网膜母细胞瘤临床病理参数的关系。结果视网膜母细胞瘤组织中 Ki-67的阳性率为66.0%（64/97）,高于正常视网膜组织的14.3%（4/28）（χ2=23.406,P <0.05）;视网膜母细胞瘤组织中 PTEN 的阳性率为53.6%（52/97）,低于正常视网膜组织的92.9%（26/28）（χ2=14.266,P <0.05）。视网膜母细胞瘤组织中 Ki-67、PTEN 的表达均与患者的分化程度、临床分期有关（P <0.05）。视网膜母细胞瘤组织中 Ki-67、PTEN 的表达呈负相关关系（r =-0.493,P <0.05）。结论 Ki-67、PTEN 的异常表达参与了视网膜母细胞瘤的侵袭和病程进展。     

人脑胶质母细胞瘤Ki-67抗原表达及其预后作用

目的探讨Ki-67抗原在人脑胶质母细胞瘤中的表达及其预后作用.方法使用S-P免疫组化方法检测31例人脑胶质母细胞瘤标本中Ki-67抗原的表达.单因素使用Kaplan-Meier法,多因素分析使用COX比例风险模型进行预后分析.结果Ki-67LI为(8.07±3.84)%.单因素及多因素分析均显示Ki-67指数是独立的预后因素.Ki-67指数≤2.5%与＞2.5%的患者生存期分别为(46.17±17.21)月、(12.43±5.01)月,P＜0.01.结论在人脑胶质母细胞瘤中,Ki-67指数不同,其预后也有显著不同.Ki-67指数＞2.5%提示预后较差.     

错配修复蛋白联合血清肿瘤标志物与Ki-67增殖指数对结直肠癌预后的临床价值

背景与目的：结直肠癌是消化系统常见的恶性肿瘤之一,近年来中国结直肠癌发病率显著升高。各项临床与病理学指标对于结直肠癌的诊断、临床分期及预后的判断提供了帮助。探讨错配修复蛋白表达联合血清肿瘤标志物与Ki-67增殖指数在结直肠癌中的相关性及对预后判断的临床价值。方法：收集复旦大学附属华东医院2014年7月—2018年6月收治的234例结直肠癌手术患者,分析其术前血清标本中肿瘤标志物癌胚抗原（carcinoembryonic antigen,CEA）、糖类抗原（carbohydrate antigen,CA）19-9、CA72-4、CA12-5水平及手术标本组织中的Ki-67增殖指数与错配修复蛋白的表达率,与结直肠癌临床病理学特征和预后的关系。结果：在234例结直肠癌患者术后标本中发生错配修复蛋白缺失表达（deficient mismatchrepair,dMMR）的共29例（12.4%）,错配修复蛋白正常表达（proficientmismatchrepair,pMMR）的有205例（87.6%）。在临床病理学指标的相关性分析中dMMR组与pMMR组在肿瘤原发部位、分化类型、分期、T分期、淋...     

survivin在乳腺癌中的表达及其与Ki-67和c-erbB-2表达的关系

目的：观察凋亡抑制蛋白survivin在乳腺癌组织中的表达,及其与c-erbB-2、Ki-67增殖指数的相关性及临床病理意义。方法：应用免疫组织化学SP法检测survivin在正常乳腺组织（20例）和乳腺癌组织（96例）中的表达以及Ki-67、c-erbB-2在乳腺癌组织中的表达。结果：survivin阳性表达乳腺癌的Ki-67增殖指数(35.32±21.28)%明显高于survivin阴性者(20.42±11.34)%,survivin表达与肿瘤细胞增殖呈正相关(P<0.01);survivin在乳腺癌组织中的阳性表达率为70.83%(68/96),正常乳腺组织未见survivin表达;survivin蛋白的表达与c-erbB-2的表达呈正相关（P<0.01）;survivin蛋白的表达与临床分期、淋巴结转移和5年生存率有关(P<0.05),与年龄、是否绝经、肿瘤大小和组织学分级均无关。结论：survivin不仅参与凋亡的调控,还促进了细胞增殖,在乳腺癌发生、发展中起重要作用,过度表达提示预后不良。     

Ki-67、VEGF和p27在急性白血病中的表达及其相关性研究

 目的　探讨Ki-67、VEGF和p27在急性白血病（AL）中的表达及其相关性。方法　采用免疫细胞化学染色测定AL患者骨髓单个核细胞中Ki-67、VEGF和p27的表达。结果　AL细胞表达Ki-67（42.48±25.78）%或VEGF（44.89±24.01）%的水平均显著高于对照组（11.40±9.94）% 或（16.90±12.54）%（P＜0.01）,而p27的表达（23.65±13.30）%明显低于对照组（50.23±22.68）%（P＜0.01）;Ki-67与VEGF及p27的表达分别呈正相关（r＝0.666,P＜0.01）和负相关（r＝-0.316,P＜ 0.05）。结论　Ki-67、VEGF和p27在AL细胞中的表达对研究AL的发生机制及其诊断有价值。     

垂体腺瘤侵袭性与p16蛋白表达及Ki-67指数的关系

探讨Ｐ１６蛋白表达及Ｋｉ－６７指数与垂体腺瘤增殖与侵袭生物学物学特性的关系。方法：应用免疫组化染色技术检测５７例垂体腺瘤中Ｐ１６及Ｋｉ－６７蛋白的表达。结果：垂体腺瘤Ｐ１６蛋白阳性率为３１．６％,侵袭性组Ｐ１６蛋白阳性率显著氏于侵袭性组。     

MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma.

PURPOSE: A number of studies have indicated that the tumor proliferation marker MIB-1 and cell cycle inhibitor p27(Kip1) expression are of prognostic importance in a variety of cancers. The present study was performed to evaluate the prognostic value of these molecules in Wilms' tumors. EXPERIMENTAL DESIGN: MIB-1 and p27(Kip1) expressions were investigated by the means of immunohistochemical analysis of 62 Wilms' tumor. Patients were preoperatively treated by chemotherapeutic agents and had a mean follow-up of 5.7 years. RESULTS: MIB-1 and p27(Kip1) were expressed in normal kidney tissues and in the three main components of Wilms' tumor, i.e., the blastemal, epithelial, and stromal cells. In Wilms' tumors, the percentage of MIB-1-positive cells in the blastema ranged between 0 and 42% (mean, 9.4%) and in the epithelial component between 0 and 53% (mean, 19.9%), with a significant difference (P < 0.01). The percentage of blastemal p27(Kip1)-positive cells ranged between 3 and 85% (mean, 55.1%) and for the epithelial component between 1 and 87% (mean, 59%). There was a significant inverse relationship between blastemal MIB-1 and p27(Kip1) expression in Wilms' tumor. Univariate analysis showed that blastemal MIB-1 and p27(Kip1) expression were indicative for clinical progression and tumor-specific survival. In a multivariate analysis, blastemal MIB-1 and p27(Kip1) protein expression proved to be an independent prognostic for clinical progression besides stage. CONCLUSIONS: It was concluded that both MIB-1-based proliferative activity and p27(Kip1) protein expression in the blastema have prognostic impact in Wilms' tumor.     

Ependymomas: MIB-1 proliferation index and survival

The biologic behavior of ependymomas is highly variable, and its correlation with histologic features is at best imprecise. This retrospective study attempted to correlate the malignant histologic characteristics of ependymomas with MIB-1 proliferation index and survival. Biopsy and resection specimens taken from 34 patients who received treatment 1972 to 1996 were histologically examined. The patients' ages range was 1 to 59 years. The histologic specimens were assessed for anaplastic features (necrosis, mitosis, vascular proliferation, cellular pleomorphism, and overlapping of nuclei) and an MIB-1 (Ki-67 antigen) proliferation index was also determined. The overall median MIB-1 proliferation index was 7.8% (range 0.1 – 62.5%). An MIB-1 of 20% was significant for a decrease in survival (RR=5.7) (p=0.0013). The median MIB-1 for patients < 20 years old was 20.6% with range (0.1, 43%), while that for patients > 20 years was 5.1% (range 0.2, 9.4%) (KW p=0.055). Three of 5 histological features evaluated were significantly associated with outcome: > 5 mitotic figures per high-power field, necrosis, and vascular proliferation, but not nuclear overlap or pleomorphism. All pathologic factors except pleomorphism were significantly related to the MIB-1 proliferation index. In brief, our data support the association of poor prognoses in ependymomas with young age, the presence of three to four anaplastic histologic features, and an MIB-1 proliferation index > 20%.     

十二指肠腺癌组织中HER-2、Ki-67的表达及与临床病理特征及预后的关系

目的:探讨HER-2、Ki-67在十二指肠腺癌组织中的表达及其与临床病理及预后的相关性。方法:选择经病理确诊的十二指肠腺癌患者51例作为研究对象,采用免疫组化方法检测癌组织标本及癌旁组织标本中HER-2、Ki-67表达情况,分析其与临床病理及预后的关系。结果:HER-2、Ki-67在癌组织中阳性表达率明显高于癌旁组织（P＜0.05）,HER-2表达情况与临床分期、原发灶直径差异有统计学意义（P＜0.05）,Ki-67表达情况与临床分期、淋巴结转移与否、分化程度、Hp感染差异有统计学意义（P＜0.05）。预后分析提示HER-2、Ki-67表达情况与十二指肠腺癌患者的预后差异具有统计学意义（P＜0.05）。Pearson相关性分析提示Ki-67与HER-2表达无相关性（P＜0.05）。结论:十二指肠腺癌中,HER-2、Ki-67呈高表达,且与患者的临床病理特征明显相关,可能是影响十二指肠腺癌患者预后的重要危险因素。     

The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas

The current WHO classification of human astrocytomas has limitations in predicting prognosis and diagnosis, and there is a need for additional factors. Several studies have investigated the clinical value of proliferative activity in these tumors, especially the Ki-67/MIB-1 labeling index (LI). The aim of this study was to review the literature on this topic to get a survey of the current experience. All studies show increasing values of Ki-67/MIB-1 LI with increasing grade of malignancy. Most of them demonstrate that MIB-1 LI differentiates well between diffuse astrocytomas WHO grade II (AII) and anaplastic astrocytomas (AA) and between AII and glioblastomas (GM), but not between AA and GM. There is, however, considerable overlap of indices between the different malignancy groups. Further, in most studies positive correlations between MIB-1 LI and survival are found, though the proposed cut-off values vary substantially between the reports. The studies reviewed report MIB-1 LI as an important prognostic factor in human astrocytomas. Due to the great spread of values between the various tumor grades, however, MIB-1 LI cannot be used as a diagnostic factor alone but should be used in combination with established criteria of histological malignancy. It may be especially useful in cases where histology reveals a low-grade astrocytoma whereas other parameters indicate a more malignant neoplasm. Thus, it is our opinion that MIB-1 LI should be a part of the routine investigation in patients with astrocytic tumors. Until larger multicenter studies based on standardized immunohistopathological procedures have been completed, each laboratory has to establish its own practice. (Pathology Oncology Research Vol 12, No 3, 143–147)     

Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer

Background The aim of the study was to identify reliable predictive biological markers for treatment outcome following neoadjuvant adriamycin/docetaxel (AT) chemotherapy in locally advanced breast cancer patients. Materials and methods This study was a phase II study on AT neoadjuvant chemotherapy in locally advanced breast cancer patients. Patients received 50 mg/m² of doxorubicin intravenously (IV) over 15 min followed by docetaxel 75 mg/m² infused over 1 h, repeated every 3 weeks for three cycles. Surgery was performed within 3–4 weeks following the last cycle of chemotherapy. We analyzed the pre-treatment and post-treatment expression levels of ER, PgR, HER-2, Ki-67 proliferation index, and p53 and examined the correlation between the markers and clinical parameters with treatment response, overall survival and relapse-free survival following neoadjuvant treatment. Results From July 2001 to September 2004, 61 patients were enrolled. The meaningful parameters adversely influencing survival were post-treatment ER(−) status (P = 0.013) and post-treatment Ki-67 index above 1.0% (P = 0.013). At the multivariate level, the post-treatment Ki-67 proliferation index ≤ 1.0 was the only meaningful prognostic factor for better survival (P = 0.033). Notably, tumors with Ki-67 index ≤ 1.0 were more likely to express ER with statistical significance (P = 0.002). Tumors with ER(+) and Ki-67 index ≤ 1.0 showed the highest survival rate, followed by ER(+) and Ki-67 index > 1.0%, ER(−) and Ki-67 ≤ 1.0%, and ER(−) and Ki-67 > 1.0% with the worst survival (P = 0.033). Conclusion Collectively, post-treatment ER status and Ki-67 proliferation index were prognostic of overall survival following neoadjuvant AT chemotherapy.     

p53 、Ki-67 在弥漫性大B 细胞淋巴瘤中的表达及相互关系

 目的 探讨p53和Ki-67在DLBCL免疫类型中的表达及相互关系。方法 采用免疫组化MaxVision法检测p53和Ki-67在DLBCL免疫类型中和反应性增生的淋巴结中的表达。结果 25例GCB中p53的阳性率为16．0％，35例non-GCB中p53的阳性率为45．7％，两者之间P〈0．01；25例GCB中Ki-67高表达4例，35例non-GCB中Ki-67高表达18例，两者之间P〈O．01；p53阳性DL-BCL20例中ki-67高表达12例，p53阴性DLBCL40例中Ki-67高表达10例，两者正相关。结论 p53、Ki-67的表达与DLBCL的免疫类型相关，GCB类型中低表达，non-GCB类型中高表达。     

乳腺癌组织中Twist及Ki-67的表达及其与乳腺癌临床病理特征的相关性

目的:探讨Twist和Ki-67在乳腺癌组织中的表达,分析两者与乳腺癌临床病理特征的相关性。方法:选取62例乳腺癌组织,20例正常组织作为对照,采用免疫组化染色法分别检测 Twist和Ki-67 的表达,并检测Twist及Ki-67在不同类型及不同分子亚型乳腺癌组织中的表达。结果:在乳腺癌组织中,Twist阳性率为37.10%,Ki-67阳性率为45.16%,均高于正常组织,差异有统计学意义（P<0.01）。乳腺癌组织中 Twist和Ki-67 在肿瘤直径、ER、PR状态及组织分级分组中表达有显著性差异（P<0.05）。结论:Twist和Ki-67在乳腺癌组织中表达一致,且均呈高表达。提示两者可能与乳腺癌恶性程度分级及侵袭力有关。     

细胞周期蛋白激酶抑制蛋白p27kip1在肿瘤预后中的研究现状

细胞增殖是可调控的，细胞周期正向和负向调节因素参与其中。目前已发现细胞周期蛋白／周期蛋白激酶抑制剂同细胞周期Ｇ１期的调控有关。这此抑制剂中，ｐ２７＾ｋｉｐ１的研究特别受重视，在Ｇ１期细胞周期蛋白／周期蛋白激酶复合物的调节中起主要作用。ｐ２７高表达可引起Ｇ１期阻滞，抑制多种癌细胞的生长。目前仅在少数种类的肿瘤中检测了ｐ２７的免疫活性。在结肠癌和乳腺癌中，ｐ２７低表达与肿瘤进展和低生存率相关。研究证明